Idarubicin Accord

Idarubicin, the active ingredient in Idarubicin Accord, is an anthracycline presented as an injectable solution for intravenous use. It is employed in the treatment of acute myeloid leukemia in adult patients, where it helps to eradicate malignant leukemic cells.

GNH USA supplies Idarubicin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe import and clinical use. It ensures compliance with EU pharmacopeial specifications and batch release testing.

Idarubicin is an anthracycline chemotherapy used primarily in the management of acute myeloid leukemia. - Acute Myeloid Leukemia (AML): induces remission by destroying proliferating leukemic blasts. - High‑risk AML subtypes: improves survival outcomes when combined with standard induction regimens. - Relapsed or refractory AML: offers therapeutic benefit in patients who have not responded to prior treatments. - Secondary AML after prior chemotherapy: provides an alternative anthracycline option for patients with therapy‑related disease. - Pediatric AML (selected cases): may be considered under specialist supervision when standard regimens are unsuitable.

Idarubicin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during treatment, often managed with anti‑emetic therapy. - Alopecia: reversible hair loss affecting scalp and body hair, typically occurring within weeks of therapy. - Myelosuppression: reduced blood cell counts leading to anemia, neutropenia or thrombocytopenia, requiring regular monitoring. - Fatigue: persistent tiredness that may affect daily activities and quality of life.

Serious or Rare Side Effects: - Cardiotoxicity: irreversible heart muscle damage that can lead to heart failure, especially with cumulative dosing. - Severe neutropenia with infection risk: profound drop in neutrophils increasing susceptibility to bacterial and fungal infections. - Anaphylactic reactions: rare hypersensitivity that may require emergency intervention, including epinephrine administration.

When using Idarubicin, clinicians should observe several precautionary measures to minimize risks. - Cardiac monitoring: perform baseline and periodic echocardiograms to detect early cardiotoxicity. - Hematologic assessment: check complete blood counts before each dose to manage myelosuppression. - Liver function evaluation: assess hepatic enzymes as Idarubicin is metabolized hepatically. - Avoid concurrent cardiotoxic agents: do not combine with other anthracyclines or high‑dose cyclophosphamide. - Use cautiously in elderly patients: adjust monitoring due to increased susceptibility to toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Idarubicin can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Idarubicin plasma levels and toxicity. - Other cardiotoxic chemotherapy (e.g., doxorubicin, high‑dose cyclophosphamide): additive risk of heart damage. - Myelosuppressive agents (e.g., cytarabine, fludarabine): can exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, heparin): heightened bleeding risk due to platelet suppression. - Drugs affecting QT interval (e.g., quinidine, sotalol): may increase risk of cardiac arrhythmias.